Why Is C5a Inflammatory Complement Inhibition Not Enough to Improve C3 Glomerulopathy?

Department of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany Correspondence: Prof. Dr. Peter F. Zipfel, email: [email protected] See related article, "Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy: Randomized, Double-Blind Clinical Trial," on pages XXX–XXX.